Solara Pharma Demands Final Payment for Rights Shares

Solara Active Pharma Sciences Ltd. has issued a second and final call notice for its partly paid-up rights equity shares, demanding payment of ₹112.50 per share by May 7, 2026. This amount includes ₹3 face value and ₹109.50 premium. Trading in these shares has been suspended since April 2, 2026, and failure to pay risks forfeiture of the shares and any amounts already paid.

This call follows a rights issue Solara Active Pharma conducted in 2023, which aimed to raise capital for working capital requirements and general corporate purposes. The company is now seeking the full payment to complete this capital infusion.

Upon successful payment by the due date, the existing partly paid-up equity shares will be converted into fully paid equity shares. This conversion will enable these shares to participate fully in future corporate actions and receive dividends.

Solara Active Pharma operates in the API manufacturing sector alongside peers such as Divi's Laboratories, Laurus Labs, Aarti Drugs, and Granules India. The company's current priority is the successful completion of this capital call from its rights issue investors.